Open Access. Powered by Scholars. Published by Universities.®
Translational Medical Research Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Hepatorenal syndrome (2)
- Acute kidney injury (1)
- Albumin (1)
- Ascites (1)
- Bisphosphonates (1)
-
- CKD (1)
- Cardiorenal syndrome (1)
- Chronic kidney disease (1)
- Cirrhosis (1)
- Creatinine (1)
- Dialysis (1)
- Exercise therapy (1)
- Hepatorenal cocktail (1)
- Ibandronate (1)
- Kidney function (1)
- Midodrine (1)
- Multiple myeloma (1)
- Nephrotoxicity (1)
- Octreotide (1)
- Pamidronate (1)
- Pharmacological diuresis (1)
- Physical activity (1)
- Renal failure (1)
- Renal insufficiency (1)
- Safety (1)
- Terlipressin (1)
- Ultrafiltration (1)
- Zaledronic acid (1)
Articles 1 - 5 of 5
Full-Text Articles in Translational Medical Research
Renal Disease Rehabilitation And Delaying Dialysis, Spencer Brown, Natalie Sterner
Renal Disease Rehabilitation And Delaying Dialysis, Spencer Brown, Natalie Sterner
Clinical Research in Practice: The Journal of Team Hippocrates
A clinical decision report using:
Greenwood SA, Koufaki P, Mercer TH, et al. Effect of exercise training on estimated GFR, vascular health, and cardiorespiratory fitness in patients with CKD: a pilot randomized controlled trial. Am J Kidney Dis. 2015;65(3):425-434. https://doi.org/10.1053/j.ajkd.2014.07.015
for a patient with non-dialysis CKD interested in slowing the progression toward necessary dialysis.
Bisphosphonates Can Be Safely Given To Patients With Hypercalcemia And Renal Insufficiency Secondary To Multiple Myeloma, Matthew J. Miller
Bisphosphonates Can Be Safely Given To Patients With Hypercalcemia And Renal Insufficiency Secondary To Multiple Myeloma, Matthew J. Miller
Clinical Research in Practice: The Journal of Team Hippocrates
A critical appraisal and clinical application of Itou K, Fukuyama T, Sasabuchi Y, et al. Safety and efficacy of oral rehydration therapy until 2 h before surgery: a multicenter randomized controlled trial. Journal of Anesthesia. 2012;26(1):20-27. doi: 10.1007/s00540-011-1261-x.
Combination Octreotide, Midodrine, And Albumin May Improve Survival In Patients With Hepatorenal Syndrome, But The Evidence Is Weak, Jacob Szafranski
Combination Octreotide, Midodrine, And Albumin May Improve Survival In Patients With Hepatorenal Syndrome, But The Evidence Is Weak, Jacob Szafranski
Clinical Research in Practice: The Journal of Team Hippocrates
A critical appraisal and clinical application of Skagen C, Einstein M, Lucey MR, Said A. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol. 2009 Aug;43(7):680-5. doi: 10.1097/MCG.0b013e318188947c
Pharmacologic Diuresis Is Safer Than Ultrafiltration For Cardiorenal Syndrome, Grace Choong
Pharmacologic Diuresis Is Safer Than Ultrafiltration For Cardiorenal Syndrome, Grace Choong
Clinical Research in Practice: The Journal of Team Hippocrates
A critical appraisal and clinical application of Bart BA, Goldsmith SR, Lee KL et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367:2296-2304. doi: 10.1056/NEJMoa1210357
It Is Reasonable To Treat Patients With Type 1 Hepatorenal Syndrome With Midodrine And Octreotide, William Kane
It Is Reasonable To Treat Patients With Type 1 Hepatorenal Syndrome With Midodrine And Octreotide, William Kane
Clinical Research in Practice: The Journal of Team Hippocrates
A critical appraisal and clinical application of Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci. 2007;52(3):742-748. doi: 10.1007/s10620-006-9312-0